Angiopoietin-like proteins in multiple sclerosis

J Neuroimmunol. 2019 May 15:330:31-34. doi: 10.1016/j.jneuroim.2019.02.006. Epub 2019 Feb 15.

Abstract

Angiopoietin-like proteins (ANGPTLs) are a group of proteins with functions in lipid metabolism, angiogenesis, and inflammation. Here, we investigated their involvement in multiple sclerosis (MS) progression and response to treatment in 100 MS patients and 77 healthy controls. ANGPTLs significantly associated with MS progression and response to therapy. High ANGPTL6 levels associated with slow disease progression and good response to fingolimod treatment and low ANGPTL4 associated with poor response to natalizumab treatment. Therefore, we propose high ANGPTL4 and 6 levels as markers for positive response to MS treatments either natalizumab or fingolimod respectively. Further investigations into their role in MS is warranted.

Keywords: Angiopoietin-like proteins; Fingolimod; Multiple sclerosis; Natalizumab.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Angiopoietin-like Proteins / blood*
  • Biomarkers / blood
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Immunologic Factors / therapeutic use*
  • Kuwait / epidemiology
  • Longitudinal Studies
  • Male
  • Multiple Sclerosis / blood*
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / epidemiology
  • Natalizumab / therapeutic use*
  • Young Adult

Substances

  • Angiopoietin-like Proteins
  • Biomarkers
  • Immunologic Factors
  • Natalizumab